“showed a trend”

Although not significantly, larger tumor volumes showed a trend toward worse locoregional control with a hazard ratio (HR = 1.63, p = 0.11) that is comparable to those previously reported by others ( 27 ).

Mice receiving E-selectin showed a trend toward reduced macrophage infiltration compared with mice receiving PBS (4.4±0.6×10 5 μm 2 in PBS group versus 3.2±0.3×10 5 μm 2 in E-selectin group, P = 0.11).

The concentration of valerate showed a trend (P = 0.11) to increase with the inclusion of MOS in the animals' diet.

A one‐month landmark analysis showed a trend toward better median OS in the patients with severe grade CIP (6.0 [95% CI 2.0–18.0] months vs. 13.0 [12.0–21.0] months, P = 0.11, N = 65; Fig 3 a,b).

1 e) and showed a trend towards a shorter OS (median 10.4 months vs 16.6 months, P = 0.11) (Fig. 1 f) than patients with a value of > 0.22.

In the MSKCC cohort, although EGFR alterations showed a trend toward better prognosis, there was no statistical significance ( p = 0.110, Figure S2 A).

LV EDVI and LV ESVI were positively correlated with EAT SFA ( p ≤ 0.02 for both), and LVEF showed a trend toward a negative correlation with EAT SFA ( p = 0.11).

Both controls and lymph node negative patients (pN0) had lower MMP8 levels than patients with moderate lymph node involvement (pN1, pN2) (p = 0.001); and showed a trend for higher MMP8 levels compared to patients with extensive lymph node involvement (pN3) and a strong predisposition to distant metastasis (p = 0.11).

The model assessing open-ended self-derivation of integration facts showed a trend in the same direction, but a weaker relation ( p = .11).

For example, NPI showed a trend independent of genotype, worsening less (2.93 points) in the DHA group than in the placebo group (5.09 points, P = 0.11).

Compared to the naïve control group, group 2 (Alum/CP15) showed the best protection against weight loss (P=0.004), while group 1 (Alum) showed a trend of protection (P=0.11, Figure 1B ).

For walking performance ( Dual-Task—Walk ), higher prefrontal ΔO 2 Hb cost showed a trend for an association with slowing of walking speed ( r = 0.28, p = 0.11; Figure 6A ), as well as with shorter stride length ( r = 0.33, p = 0.06; Figure 6B ).

After SY treatment, HOMA‐IR showed a trend to decrease compared with the HFD group (4.16 ± 2.08 vs 6.45 ± 4.26, P = 0.11).

Six of the nine maxVel bins showed a trend for the hypothesized effect ( p < 0.11), however, only one maxVel bin showed significant difference, after correcting for multiple comparisons.

Among the locations, only subserous leiomyomas showed a trend towards a reduced probability of DO ( p = 0.11, versus submucous and p = 0.12, versus intramural).

Pregnancy termination due to reaching 34 weeks of gestation showed a trend toward increased odds (OR = 4.02, 95% CI: 0.74–21.99, p = 0.11), but did not reach statistical significance in this category.

Those who received the rifaximin showed a trend for decreased rates of recurrence of CDI (31% versus 15%, p = 0.11). 29 Adding the option of a rifaximin chaser provided the practicing clinician with another choice for those with multiply recurrent CDI.

The BVS showed a trend toward a wider external elastic membrane area (12.86 ± 3.25 mm 2 ) when compared with EES/BES (11.58 ± 3.69 mm 2 ; p = 0.11).

Women had significantly better 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog, 70-point scale) scores than men ( P = 0.001) and showed a trend toward younger age ( P = 0.11).

There was a mean difference of 45 minutes in total sleep time between the PRM- and placebo-treated groups that showed a trend for a significant improvement ( P =0.11; data not shown).

In utero and early life exposed mice (DE/FA) showed a trend of increased ventricle weights normalized to tibia length (p = 0.11), but significance was not achieved.

In NT1, patients showed a trend towards compressed onset (mean Z-AUC − 0.7 ± 1.5 vs 0.0 ± 0.7 in controls; p ≈ 0.11).

However, both control hospitals and MET hospitals showed a trend toward a decreased percentage of ICU admissions being secondary to CAs ( P = 0.11 and P = 0.1, respectively).

In patients with triple-negative breast cancer (TNBC), high TRPS1 expression was significantly associated with worse overall survival (OS) (HR = 2.3, p = 0.037) and showed a trend toward poorer recurrence-free survival (RFS) (HR = 1.7, p = 0.11), although the latter did not reach statistical significance (Fig. 1 A).

MODS from day 3 to day 7 showed a trend toward improvement in the centhaquine group (MODS 1.37 to 0.82, p = 0.11) and toward deterioration in the control group (MODS 1.14 to 1.73) [ 30 ].